Bispecific and trispecific antibodies show efficacy in multiple myeloma, moving into earlier lines of therapy.

During a live event, Moshe C. Ornstein, MD, MA, considered the trial design and outcomes of 2 trials of combination regimens ...

Future SCLC treatment may involve combining T-cell engagers with immune checkpoint inhibitors to enhance patient outcomes.

In an interview with Targeted Oncology, David J. Benjamin, MD, discussed findings on the global oncology workforce and their ...

OBI-902, targeting TROP2, gains FDA orphan drug status for cholangiocarcinoma, a rare cancer with poor prognosis and limited treatments. Orphan drug designation provides benefits like tax credits and ...

DPI-4452 targets CAIX in tumors, offering noninvasive diagnostic potential for ccRCC with favorable tolerability. The agent is part of a theranostic pair wi ...

FDA fast track designation facilitates expedited development of DPTX3186, recognizing its potential to address serious unmet medical needs in gastric cancer treatment. DPTX3186 gains FDA fast track ...

Epcoritamab, rituximab, and lenalidomide combination is approved for relapsed/refractory follicular lymphoma, marking a first in bispecific antibody second-line treatments. The EPCORE FL-1 study ...

Ongoing research in renal cell carcinoma (RCC) suggests that hypoxia-inducible factor 2-alpha (HIF-2α) inhibitors are poised ...

Benjamin, MD, discussed findings on the global oncology workforce and their implications of insufficient access to cancer ...

A novel immune-based therapy shows 100% response rates in newly diagnosed multiple myeloma patients, highlighting its ...

Pertuzumab-dpzb is the first interchangeable biosimilar to pertuzumab, enhancing treatment accessibility for HER2-positive ...